drugset / Trial / NCT01423838

Summary

Null hypothesis of the trial is that there is no difference between solifenacin and oxybutynin with respect to efficacy, side effects, patient satisfaction and quality of life measures in patients with overactive bladder.

Timeline

Start
2011-09
Primary completion
2012-09
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Oxybutynin Small molecule 5 mg Oral
Comparator Solifenacin Small molecule 5 mg Oral

Indications